Armistice Capital, LLC Increases Stake in Bluejay Diagnostics, Inc. to 4.99%

On May 15, 2026, Armistice Capital, LLC and Steven Boyd filed a Schedule 13G/A regarding their holdings in Bluejay Diagnostics, Inc. (BJDX). The filing reports that the reporting persons beneficially own 51,061 shares of common stock, representing a 4.99% ownership stake in the company. This reflects an increase from a previously reported 0.0% position. Armistice Capital, LLC serves as the investment manager for the Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to have beneficial ownership. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The reporting persons share voting and dispositive power over the reported 51,061 shares. The event triggering this filing occurred on March 31, 2026.